Loading organizations...
§ Private Profile · Wedding, Berlin, Germany
Schering AG is a company.
Key people at Schering AG.
Schering AG operates as a research-centered pharmaceutical company, developing and manufacturing a broad portfolio of medical products. Its core focus encompasses gynaecology and andrology, specialty therapeutics, diagnostic devices, nuclear medicine, and oncology. The company is particularly known for its combined oral contraceptive pills, the interferon-beta treatment Betaferon, and the paramagnetic contrast agent Magnevist, which address significant medical needs across various patient populations.
Ernst Christian Friedrich Schering founded the company in 1851, initially opening the Grüne Apotheke in Berlin. This venture evolved into a chemical factory, formally incorporated as Chemische Fabrik auf Actien (formerly E. Schering) in 1871. Schering's insight was to expand from a retail pharmacy into the industrial production of various chemicals and pharmaceuticals, laying the groundwork for its subsequent growth into a major global player in the healthcare sector.
Patients and medical professionals worldwide benefit from Schering AG’s diverse range of pharmaceutical solutions. The company's vision centers on providing tailor-made products for individual medical needs, striving to advance patient care through continuous innovation and focused therapeutic development. Its legacy underscores a commitment to addressing complex health challenges through dedicated scientific research and development.
Key people at Schering AG.
Schering AG was a pioneering German pharmaceutical and chemical company founded in 1851, renowned for innovations in hormones, sulfonamides, X-ray contrast media, and agrochemicals.[1][2][3] It grew from a small Berlin pharmacy into a multinational leader with over 25,000 employees across 160 subsidiaries by 2005, achieving €5.3 billion in sales before its 2006 acquisition by Bayer.[5] The company served global markets in pharmaceuticals, industrial chemicals, and electroplating, solving key challenges in medical treatments like gout medications and female hormones while navigating wartime disruptions.[1][2]
Ernst Schering, a pharmacist, opened the *Grüne Apotheke* (Green Pharmacy) in Berlin's Chausseestraße in 1851, initially focusing on chemical preparations.[1][2][3] By 1871, he incorporated it as *Chemische Fabrik auf Actien (vormals E. Schering)*, expanding into industrial production with a new site in 1864 that included a technical laboratory for pharmaceuticals and chemicals.[5] Early traction came from supplying pharmaceuticals during the Franco-Prussian War and launching its first specialty product—a gout medication—in 1890, shortly after Schering's death in 1889.[1][2]
Pivotal moments included diversification into electroplating (1901), agrochemicals (1920s), and female hormones (late 1920s), alongside mergers like the 1937 amalgamation with *Kokswerke und Chemische Fabriken AG* and *Schering-Kahlbaum AG*, adopting the name Schering AG.[1][3] World War II brought severe setbacks: factories were destroyed, U.S. subsidiaries seized under the Trading with the Enemy Act, and patents lost globally, but the company rebuilt post-war, repurchasing subsidiaries despite East German expropriations.[2][4]
Schering rode early waves of the chemical-pharmaceutical revolution, embodying Germany's pre-WWI "new economy" in knowledge-based industries through global exports and facilities abroad.[6] Its timing capitalized on 19th-century industrialization and 20th-century medical advances, like hormones amid rising demand for women's health solutions, while market forces favored versatile chemical firms amid agrochemical booms.[1][3] The company influenced the ecosystem by pioneering R&D models—setting up technical labs early—and participating in joint ventures, mergers, and "communities of interest," which shaped Germany's heavy industry-linked organization and transnational chemical trade.[3][5][6] Despite WWII disruptions, its recovery reinforced Europe's post-war pharma resurgence.
Schering AG's legacy as an independent innovator ended with its 2006 Bayer acquisition, integrating its Berlin-Wedding headquarters and archives into a larger pharma giant.[5] Post-merger, its hormone and contrast media expertise likely bolstered Bayer's portfolio amid ongoing trends in personalized medicine and biologics. Evolving regulatory scrutiny on historical products like Primodos and global consolidation will shape its inherited influence, but Schering's foundational R&D ethos continues driving pharmaceutical progress from a small pharmacy to multinational scale.[3]
